淋巴细胞上清抗体可区分RSV疫苗诱导与自然感染预存中和抗体
研究纳入近期接种新型RSV候选疫苗的年轻成人,建立淋巴细胞上清抗体(ALS)功能检测法,直接测定外周血单核细胞培养上清的中和活性。血清和鼻样本中RSV特异性抗体背景分布广泛,掩盖了接种两周后的疫苗特异性反应;ALS基线无RSV特异性抗体,但每剂疫苗后七天均出现明确疫苗特异性抗体反应,且该功能活性定量不受自然暴露预存抗体干扰。
要点
- 血清和鼻样本中RSV特异性抗体背景广泛,掩盖接种两周后的疫苗特异性反应。
- ALS样本基线无RSV特异性抗体,每剂疫苗后七天出现明确疫苗特异性抗体反应。
- ALS中疫苗特异性抗体显示体外功能活性,其定量不受自然暴露预存抗体干扰。
核心结论
- ALS功能检测可区分RSV疫苗诱导的中和抗体与自然感染预存抗体,是评估RSV疫苗功能免疫反应的有前景新方法。
研究设计与样本
- 研究纳入近期接种新型RSV候选疫苗的年轻成人,采集外周血单核细胞培养上清(ALS)直接检测病毒中和活性,并用ELISA测定鼻和血清样本抗体后与ALS法比较。
主要发现
- 血清和鼻样本中RSV特异性抗体呈广泛背景分布,掩盖了接种两周后测得的疫苗特异性反应。
- ALS样本基线未观察到RSV特异性抗体,但每剂疫苗给药后七天均观察到明确的疫苗特异性抗体反应。
- ALS中疫苗特异性抗体显示体外功能活性,且该功能活性的定量不受自然暴露预存抗体干扰。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory illness in infants. There is no effective vaccine and the only effective treatment available is the monoclonal antibody palivizumab which reduces the risk of severe RSV disease in prematurely born infants. However, palivizumab is too costly to allow for wide implementation and thus treatment is restricted to supportive care. Despite extensive efforts to develop a vaccine, progress has been hindered by the difficulty in measuring and assessing immunological correlates of RSV vaccine efficacy in the presence of high levels of pre-existing RSV antibodies. METHODS: Here we describe a new method for measuring the functional activity of antibodies induced by vaccination distinct from pre-existing antibodies. Antibodies in lymphocyte supernatants (ALS) from the cultured peripheral blood mononuclear cells (PBMCs) of young adults who had recently been vaccinated with a novel RSV candidate vaccine were directly assayed for virus neutralising activity. An ELISA method was used to measure antibodies in nasal and serum samples and then compared with the adapted ALS based method. RESULTS: There was a wide background distribution of RSV-specific antibodies in serum and nasal samples that obscured vaccine-specific responses measured two weeks after vaccination. No RSV-specific antibodies were observed at baseline in ALS samples, but a clear vaccine-specific antibody response was observed in ALS seven days after the administration of each dose of vaccine. These vaccine-specific antibodies in ALS displayed functional activity in vitro, and quantification of this functional activity was unperturbed by pre-existing antibodies from natural exposure. The results demonstrate a promising new approach for assessing functional immune responses attributed to RSV vaccines.
引用
- Gerretsen HE, Capone S, Vitelli A, et al. Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. Vaccine. 2018. PMID: 30318168. doi:10.1016/j.vaccine.2018.09.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。